Fairmount Funds Management LLC - Insider Trading & Ownership

Location
200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
Summary
The estimated value of insider holdings of Fairmount Funds Management LLC is at least $354M dollars as of November 17, 2025. Fairmount Funds Management LLC is the Director, 10%+ Owner of Viridian Therapeutics, Inc.\DE and owns shares of Viridian Therapeutics, Inc.\DE (VRDN) stock worth about $86.1M. Fairmount Funds Management LLC is the Director of Cogent Biosciences, Inc. and owns shares of Cogent Biosciences, Inc. (COGT) stock worth about $81M. Fairmount Funds Management LLC is the Director, 10%+ Owner of Oruka Therapeutics, Inc. and owns shares of Oruka Therapeutics, Inc. (ORKA) stock worth about $54.3M. Fairmount Funds Management LLC is the Director, 10%+ Owner of Jade Biosciences, Inc. and owns shares of Jade Biosciences, Inc. (JBIO) stock worth about $48.1M. Fairmount Funds Management LLC is the Director of Dianthus Therapeutics, Inc. /DE/ and owns shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) stock worth about $42.4M. Fairmount Funds Management LLC is the Director of Zenas BioPharma, Inc. and owns shares of Zenas BioPharma, Inc. (ZBIO) stock worth about $42M. Fairmount Funds Management LLC is the Director, 10%+ Owner of CRESCENT BIOPHARMA, INC. and owns shares of GLYCOMIMETICS INC (GLYC) stock worth about $347K.
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
All Insider Reports
All Insider Reports

Ownership of Fairmount Funds Management LLC

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
VRDN Viridian Therapeutics, Inc.\DE Director, 10%+ Owner $86.1M +$10M +13.1% Oct 23, 2025
COGT Cogent Biosciences, Inc. Director $81M +$25M +44.6% Jul 10, 2025
ORKA Oruka Therapeutics, Inc. Director, 10%+ Owner $54.3M Sep 17, 2025
JBIO Jade Biosciences, Inc. Director, 10%+ Owner $48.1M Oct 6, 2025
DNTH Dianthus Therapeutics, Inc. /DE/ Director $42.4M Sep 27, 2024
ZBIO Zenas BioPharma, Inc. Director $42M +$6.01M +16.7% Oct 7, 2025
GLYC GLYCOMIMETICS INC Director, 10%+ Owner $347K Jun 23, 2025
APGE Apogee Therapeutics, Inc. Director Jun 17, 2025
GLTO Galecto, Inc. Director, 10%+ Owner Nov 10, 2025
SYRE Spyre Therapeutics, Inc. Director May 29, 2025

Insider Transactions Reported by Fairmount Funds Management LLC:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.